IndraLab

Statements


| 2

reach
"For example, the knockdown of USP5, which allows the competitive binding of accumulated unanchored polyubiquitin, inhibits proteasomal recognition sites on P53, thereby inhibiting the proteasomal-mediated degradation of p53 and increasing its transcriptional activity to negatively regulate p53-related pathways [48] (Figure 2A)."

reach
"Overexpression of USP5 rescued neuroblastoma cells from the cytopathic effects of the combination and reduced unanchored polyubiquitin, suggesting USP5 is a therapeutic target of the combination."